News
Video
Author(s):
IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma
Revisit the OncLive On Air Episodes From February 2024
Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP
FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL